News. 15. Nu. Cana Announces First Patients Enrolled in Phase 2 Study of Acelarin in a Platinum Resistant Ovarian Cancer. EDINBURGH, United Kingdom, Nov. GLOBE NEWSWIRE Nu. Cana plc NASDAQ NCNA announced the enrollment of the first patients in both the United States and the United Kingdom in its PRO 1. Acelarin NUC 1. Hugh Griffith, Nu. Canas Chief Executive Officer, stated The initiation of this Phase 2 study of Acelarin in both the US and the UK is a major step in the expansion of the Nu. Cana product pipeline and advances our strategy of rapidly developing our Pro. Tides to benefit cancer patients globally. We are grateful to the patients and clinicians who are making this study possible. The PRO 1. 05 study will enroll up to 6. Responses to StemCell Therapy for Retinitis Pigmentosa Safe Thus Far in Early Human Study. Housing in the Santa Clara region of California is insanely expensive. Tech companies have taken to building modern day versions of mill towns just so their employees. Initial Prognosis What Now So, you have been diagnosed with Fatty Liver Disease, and now youre full of questions and wondering where to go from here. Type or paste a DOI name into the text box. Click Go. Your browser will take you to a Web page URL associated with that DOI name. Send questions or comments to doi. Aduro Biotech Announces Promising Preclinical Data that Validate AntiCTLA4 Antibody ADU1604. BERKELEY, Calif., Nov. GLOBE NEWSWIRE Aduro Biotech. Gmail is email thats intuitive, efficient, and useful. GB of storage, less spam, and mobile access. Hyperbaric Oxygen Therapy Providers and Treatment Centers In The United States. Not Registered Yet Benefits of Registration Include A Unique User Profile that will allow you to manage your current subscriptions including. Original Article. A Randomized, Controlled Trial of Methylprednisolone or Naloxone in the Treatment of Acute SpinalCord Injury Results of the Second National. Optic Nerve Treatment Trial Results San Jose' title='Optic Nerve Treatment Trial Results San Jose' />Patients will receive Acelarin on day 1, 8 and 1. The primary endpoint of the study will be Objective Response Rate, and secondary endpoints include Duration of Response, Progression Free Survival, Overall Survival and safety parameters. Part one of the study will enroll up to 2. In part two of the study, Nu. Cana will select one of these doses and enroll at least an additional 2. Nu. Cana expects to announce interim data from this study in 2. More information about this study may be found at https clinicaltrials. NCT0. 31. 46. 66. Professor Bradley J. Monk of Arizona Oncology and co Chief Investigator of PRO 1. Platinum resistant ovarian cancer remains an area of significant unmet medical need and we are excited to participate in this study and advance Acelarin as a potential treatment for women with ovarian cancer. Acelarins ability to overcome key cancer cell resistance mechanisms resulting in significantly greater levels of the active anti cancer metabolite differentiates it from other treatment approaches. Professor Charlie Gourley, of the University of Edinburgh and co Chief Investigator of PRO 1. Acelarin has shown meaningful clinical activity in advanced recurrent ovarian cancer and has been well tolerated in clinical studies to date. We are pleased to be a part of this important clinical study. Acelarin is a potential first in class Pro. Tide that has been evaluated in over 1. In the first in human Phase 1 dose ranging PRO 0. Acelarin was well tolerated and achieved a 7. Acelarin achieved a disease control rate of 9. PRO 0. 01 study. This was followed by the Phase 1b dose ranging PRO 0. Acelarin in combination with carboplatin achieved a 9. Apellis Pharmaceuticals Announces Closing of its Initial Public Offering. CRESTWOOD, Ky., Nov. GLOBE NEWSWIRE Apellis Pharmaceuticals, Inc. NASDAQ APLS, a clinical stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced the closing of its initial public offering of 1. The total gross proceeds to Apellis were approximately 1. Apellis. All of the shares were sold by Apellis. In addition, Apellis granted the underwriters a 3. The shares commenced trading on the NASDAQ Global Select Market under the ticker symbol APLS on Thursday, November 9, 2. Citigroup, J. P. Morgan and Evercore ISI acted as joint book running managers for the offering. A registration statement relating to the securities sold in this offering was declared effective by the Securities and Exchange Commission on November 8, 2. The offering was made only by means of a prospectus. When available, copies of the final prospectus relating to the offering may be obtained by contacting Citigroup Global Markets Inc., co Broadridge Financial Services, 1. Long Island Avenue, Edgewood, NY 1. J. P. Morgan Securities LLC, co Broadridge Financial Solutions, 1. Long Island Avenue, Edgewood, NY 1. Evercore Group L. L. C., Attention Equity Capital Markets, 5. East 5. 2nd Street, 3. Floor, New York, NY 1. This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Apellis Pharmaceuticals, Inc. C3, the central protein in the complement cascade. Aduro Biotech Announces Promising Preclinical Data that Validate Anti CTLA 4 Antibody ADU 1. BERKELEY, Calif., Nov. GLOBE NEWSWIRE Aduro Biotech, Inc. Nasdaq ADRO, a biopharmaceutical company with three distinct immunotherapy technologies, today announced data from preclinical studies with ADU 1. CTLA 4 monoclonal antibody. Data from these in vitro and in vivo studies demonstrate the potency of ADU 1. Billing Software For Telecom Companies In New York on this page. T cell dependent antibody responses. These data, which will be highlighted later today in a poster presentation Poster 3. ND Annual Meeting of the Society for Immunotherapy of Cancer SITC, underscore the potential application of ADU 1. These data from preclinical studies of ADU 1. CTLA 4 product candidate derived from our proprietary B select antibody platform, are encouraging and provide support to file an Investigational New Drug Application to advance ADU 1. Andrea van Elsas, Ph. D., chief scientific officer of Aduro Biotech. As a company with multiple programs and proprietary technology platforms, we are well positioned to leverage our product candidates, as monotherapies and in rational combinations, to develop new treatment options for patients in need. Synlogic Reports Positive Top Line Phase 1 Data Demonstrating Safety and Tolerability and Proof of Mechanism in Healthy Volunteers for SYNB1. Synthetic Biotic. TM Medicine for the Treatment of Hyperammonemia. CAMBRIDGE, Mass. BUSINESS WIRE Nov. Synlogic, Inc. ,Nasdaq SYBX a clinical stage drug discovery and development company applying synthetic biology to probiotics to develop novel Synthetic Biotic medicines, today announced positive top line clinical data from its Phase 1 placebo controlled single SAD and multiple ascending dose MAD clinical trial of SYNB1. The trial successfully met the primary objectives demonstrating safety and tolerability in healthy volunteers and identifying the maximum tolerated dose. Furthermore, proof of mechanism was demonstrated by a clear signal in a plasma nitrogen endpoint. SYNB1. 02. 0, is a novel, first in class, Synthetic Biotic medicine that is orally delivered and designed to treat elevated blood ammonia levels, or hyperammonemia, in genetic urea cycle disorders UCD or in chronic liver disease. The positive data from our Phase 1 study in healthy volunteers, demonstrates that SYNB1. Aoife Brennan, M. B., B. Ch., Synlogics chief medical officer. These data support the hypothesis that SYNB1. UCDs or liver disease, and will inform dose selection in our planned Phase 1b2a study of SYNB1. This first in human study represents a significant milestone for our new class of Synthetic Biotic medicines and demonstrates that they can operate from the gastrointestinal tract to metabolize systemic toxins, said JC Gutirrez Ramos, Ph. D., Synlogics president and chief executive officer. We look forward to evaluating SYNB1. SYNB1. 61. 8 for the treatment of phenylketonuria into clinical trials in 2. SYNB1. 02. 0 was safe and well tolerated in subjects in multiple ascending dose cohorts who received total daily doses of up to 1. CFU for 1. 4 days. There have been no serious adverse events SAEs, and no cases of infection with the bacteria in this study.